Immune oncology, immune responsiveness and the theory of everything
Authors:
- Tolga TuranTTTolga Turan
- Deepti KannanDKDeepti Kannan
- Maulik PatelMPMaulik Patel
- J. Matthew BarnesJBJ. Matthew Barnes
- Sonia G. TanlimcoSTSonia G. Tanlimco
- Rongze LuRLRongze Lu
- Kyle HalliwillKHKyle Halliwill
- Sarah KongpachithSKSarah Kongpachith
- Douglas E. KlineDKDouglas E. Kline
- Wouter HendrickxWHWouter Hendrickx
- Alessandra CesanoACAlessandra Cesano
- Lisa H. ButterfieldLBLisa H. Butterfield
Open Access
- 5 June 2018
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 6 (1) , 50
Abstract
Anti-cancer immunotherapy is encountering its own checkpoint. Responses are dramatic and long lasting but occur in a subset of tumors and are largely dependent upon the pre-existing immune contexture of individual cancers. Available data suggest that three landscapes best define the cancer microenvironment: immune-active, immune-deserted and immune-excluded. This trichotomy is observable across most solid tumors (although the frequency of each landscape varies depending on tumor tissue of origin) and is associated with cancer prognosis and response to checkpoint inhibitor therapy (CIT). Various gene signatures (e.g. Immunological Constant of Rejection - ICR and Tumor Inflammation Signature - TIS) that delineate these landscapes have been described by different groups. In an effort to explain the mechanisms of cancer immune responsiveness or resistance to CIT, several models have been proposed that are loosely associated with the three landscapes. Here, we propose a strategy to integrate compelling data from various paradigms into a “Theory of Everything”. Founded upon this unified theory, we also propose the creation of a task force led by the Society for Immunotherapy of Cancer (SITC) aimed at systematically addressing salient questions relevant to cancer immune responsiveness and immune evasion. This multidisciplinary effort will encompass aspects of genetics, tumor cell biology, and immunology that are pertinent to the understanding of this multifaceted problem.Keywords
This publication has 91 references indexed in Scilit:
- Interactions between immunity, proliferation and molecular subtype in breast cancer prognosisGenome Biology, 2013
- Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse modelJournal of Experimental Medicine, 2013
- IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+ Th17 cellsJournal of Experimental Medicine, 2012
- Expression of NF-κB p50 in Tumor Stroma Limits the Control of Tumors by Radiation TherapyPLOS ONE, 2012
- The stable traits of melanoma genetics: an alternate approach to target discoveryBMC Genomics, 2012
- The microenvironment in breast cancer progression: biology and implications for treatmentBreast Cancer Research, 2011
- Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphataseBMC Cancer, 2010
- Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824Cancer Research, 2009
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- The immunologic constant of rejectionTrends in Immunology, 2008